The effect of coffee consumption on insulin sensitivity and other biological risk factors for type 2 diabetes: a randomized placebo-controlled trial

• Published in: The American journal of clinical nutrition Vol. 111; no. 2; pp. 448 - 458
• Main Authors: Alperet, Derrick Johnston, Rebello, Salome Antonette, Khoo, Eric Yin-Hao, Tay, Zoey, Seah, Sharna Si-Ying, Tai, Bee-Choo, Tai, E-Shyong, Emady-Azar, Shahram, Chou, Chieh Jason, Darimont, Christian, van Dam, Rob M
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2020; Oxford University Press; American Society for Clinical Nutrition, Inc
• Subjects: Adiponectin; Adult; adult-onset diabetes mellitus; Aged; Body fat; Body weight; Coffee; Consumption; Creatinine; Cups; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2; Fasting; Female; Females; Glucose; Glucose metabolism; Health risks; Humans; hyperinsulinemic euglycemic clamp; Insulin; Insulin - metabolism; Insulin Resistance; insulin sensitivity; Male; Males; metabolic health; Metabolism; Middle Aged; Overweight; Randomization; Reduction; Risk analysis; Risk Factors; Sensitivity; type 2 diabetes; PP; T2DM; Mbw; Mffm; FM; M-value; COMETH; DXA; FFM; M/Ibw; M/I ratio; insulin sensitivity; metabolic health; type 2 diabetes; adult-onset diabetes mellitus; Adipo-IR; coffee; M/Iffm; BIA; CGA; insulin resistance; humans; bpm; hyperinsulinemic euglycemic clamp
• ISSN: 0002-9165; 1938-3207; 1938-3207
• DOI: 10.1093/ajcn/nqz306

In observational studies, coffee consumption has been consistently associated with a lower risk of type 2 diabetes mellitus. Trials examining the effect of coffee consumption on glucose metabolism have been limited by the use of surrogate insulin sensitivity indices, small sample sizes, lack of blinding, and short follow-up duration. We aimed to overcome limitations of previously conducted coffee trials in a randomized placebo-controlled trial of the effect of coffee consumption on insulin sensitivity. We conducted a 24-wk randomized placebo-controlled trial in 126 overweight, non–insulin sensitive (HOMA-IR ≥1.30), Chinese, Malay, and Asian-Indian males and females aged 35–69 y. Participants were randomly assigned to receive 4 cups of instant regular coffee (n = 62) or 4 cups of a coffee-like placebo beverage (n = 64) per day. The primary outcome was the amount of glucose metabolized per kilogram of body weight per minute (Mbw) assessed during steady-state conditions with a hyperinsulinemic euglycemic clamp. Secondary outcomes included other clamp-based insulin sensitivity measures, biological mediators of insulin sensitivity, and measures of fasting glucose metabolism. Coffee consumption did not significantly change insulin sensitivity compared with placebo (percentage mean difference in Mbw = 4.0%; 95% CI: −8.3, 18.0%; P = 0.53). Furthermore, no significant differences in fasting plasma glucose (2.9%; 95% CI: −0.4, 6.3%; P = 0.09) or biological mediators of insulin resistance, such as plasma adiponectin (2.3%; 95% CI: −1.4, 6.2%; P = 0.22), were observed between coffee and placebo groups over 24 wk of intervention. Participants in the coffee arm experienced a loss of fat mass (FM) (−3.7%; 95% CI: −6.3, −1.1%; P = 0.006) and reduction in urinary creatinine concentrations (−21.2%; 95% CI: −31.4, −9.5%; P = 0.001) compared with participants in the placebo arm over 24 wk of intervention. Consuming 4 cups/d of caffeinated coffee for 24 wk had no significant effect on insulin sensitivity or biological mediators of insulin resistance but was associated with a modest loss of FM and reduction in urinary creatinine concentrations. This trial was registered at clinicaltrials.gov as NCT01738399. Registered on November 28, 2012. Trial sponsor: Nestlé Research, Lausanne, Switzerland. Trial site: National University of Singapore.